A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/119, 167/256
A61K 31/325 (2006.01)
Patent
CA 1200490
ABSTRACT Dithiocarbamic compounds, administered about 0.5 to about 6 hours after Pt(II) compound, have been found to counter the toxicity of the platinum in multicellular organisms (e.g. mammals). Such compositions suitable for intravenous or intraperitoneal administration have been found to have this salutary effect. For example, neoplastic growths in mammals can be treated with cis-diamine or cis-diammine Pt(II) complexes with greatly lessened risk of nephrotoxicity and damage to the digestive system of the mammal, provided the dithiocarbamic compound is timely (and preferably parenterally) administered. Particularly effective dithiocarbamic compounds are monomeric (e.g. Image , where M? is a pharmaceutically acceptable cation and R1 and R2 are lower aliphatic or cycloaliphatic groups) or, less preferably, dimeric, e.g. Image , wherein R1 and R2 are as defined previously, and R3 and R4 are defined in the same manner as R1 and R2. These dithiocarbamic compounds do not significantly reduce the desired effects of the Pt(II) compounds (particularly when the dithiocarbamic compound is intravenously administered), despite their effectiveness in reducing harmful side effects.
463251
Ridout & Maybee Llp
The Regents Of The University Of Minnesota
LandOfFree
Compositions for the inhibition of undesired effects of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for the inhibition of undesired effects of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the inhibition of undesired effects of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1232125